Lexaria Bioscience (LEXX, Financial) has provided a strategic update on its advancements in glucagon-like peptide-1 (GLP-1) technology, which potentially holds significant implications for the pharmaceutical industry. This follows recent developments by major players like Pfizer and Eli Lilly.
Lexaria's proprietary DehydraTECH technology focuses on enhancing the performance of oral GLP-1 drugs. This innovation aims to offer a preferred alternative to traditional injections while minimizing adverse events—a primary reason patients discontinue GLP-1 treatments. Lexaria has already demonstrated improved delivery performance in human tests with Novo Nordisk's Rybelsus, the only currently available orally dosed GLP-1 medication.
On April 14, 2025, Pfizer announced the discontinuation of its development of danuglipron, an oral GLP-1 candidate, due to liver injury concerns in a clinical trial. This setback follows an earlier halt in December 2023, when another study of danuglipron was stopped due to adverse side effects. Pfizer has encountered similar challenges with its GLP-1 candidate lotiglipron, which also caused elevated liver enzymes in patients.
In contrast, Eli Lilly has reported success with its orally dosed GLP-1 drug, which demonstrated significant reductions in blood sugar and body weight over a 40-week phase 3 trial. This news led to a remarkable $100 billion increase in Eli Lilly's market valuation. Despite this progress, their drug still showed gastrointestinal side effects, such as nausea, diarrhea, and vomiting, in some patients.
Lexaria's ongoing research with its DehydraTECH-GLP-1 processing shows promising results in reducing such side effects. Previous studies indicated improvements with major GLP-1 drugs like tirzepatide and semaglutide, and Lexaria is now pilot-testing liraglutide with DehydraTECH technology. These efforts underline Lexaria's potential role in advancing the development of safer and more effective oral GLP-1 treatments.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 2 analysts, the average target price for Lexaria Bioscience Corp (LEXX, Financial) is $7.50 with a high estimate of $8.00 and a low estimate of $7.00. The average target implies an upside of 413.70% from the current price of $1.46. More detailed estimate data can be found on the Lexaria Bioscience Corp (LEXX) Forecast page.
Based on the consensus recommendation from 1 brokerage firms, Lexaria Bioscience Corp's (LEXX, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Lexaria Bioscience Corp (LEXX, Financial) in one year is $2.14, suggesting a upside of 46.58% from the current price of $1.46. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Lexaria Bioscience Corp (LEXX) Summary page.
